TARGAZYME, INC.

Basic Information

*(FY14 USE 10008420)
CARLSBAD, CA, 92011-4402

Company Profile

n/a

Additional Details

Field Value
DUNS: 617462234
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: Y
Number of Employees: 8


  1. Therapeutic Potential and Targeted Homing of ECSOD-MSCs in Animal Model of Mucositi

    Amount: $224,932.00

    DESCRIPTION (provided by applicant): In the present submission we are requesting funding to support studies designed to assess proof-of-concept for a novel cell-based approach that possesses the poten ...

    SBIR Phase I 2014 Department of Health and Human Services
  2. Novel cell-based Restorative Approach in Treatment of Diabetes-related Retinopath

    Amount: $215,739.00

    DESCRIPTION (provided by applicant): Retinal vascular diseases remain a common cause of vision loss and blindness with diabetes as the most common condition leading to retinopathy in adults in Western ...

    SBIR Phase I 2014 Department of Health and Human Services
  3. Increased Therapeutic Potential of Migrating Neural Stem Cells and ASC101 Treatment

    Amount: $335,440.00

    DESCRIPTION (provided by applicant): Multiple sclerosis (MS) affects 1 in 1000 individuals in the US and is characterized by progressive sensory, motor and cognitive impairments. These functional defi ...

    SBIR Phase I 2013 Department of Health and Human Services
  4. ASC101 Enhancement of Regenerative Capacity of Amniotic Fluid-derived Stem Cells

    Amount: $156,754.00

    DESCRIPTION (provided by applicant): In the present STTR we propose to investigate two novel approaches in our exploration of the therapeutic and regenerative potential of cell-based medicine. Further ...

    STTR Phase I 2012 Department of Health and Human Services
  5. Enhanced Engraftment with Fucosylation of Cord Blood and Mesenchymal Stem Cells

    Amount: $290,908.00

    DESCRIPTION (provided by applicant): Three primary sources of hematopoietic stem cells (HSCs) are routinely used in HSC therapy. These include mobilized peripheral blood, bone marrow and umbilical cor ...

    SBIR Phase I 2011 Department of Health and Human Services
  6. Ex Vivo Fucosylation of Cord Blood with FTVII and Enhanced Hematopoietic Recovery

    Amount: $347,580.00

    DESCRIPTION (provided by applicant): The three primary sources of hematopoietic stem cells (HSCs) for bone marrow transplant are: mobilized peripheral blood, bone marrow, and umbilical cord. While eac ...

    SBIR Phase I 2011 Department of Health and Human Services
  7. Novel Approach to Enhance Cord Blood-Mediated Bone Marrow Homing and Engraftment

    Amount: $193,658.00

    DESCRIPTION (provided by applicant): Despite significant recent government and private-sector efforts to improve the current state of the art in bone marrow transplants, many patients still suffer fro ...

    SBIR Phase I 2008 Department of Health and Human Services
  8. Standard Robot Platform Designed for Unstructured Environment Research

    Amount: $74,516.00

    Robotic researchers currently are using insufficient and varying robot platforms to investigate issues crucial to the successful development of a remote reconnaissance tool for the urban search and re ...

    SBIR Phase I 2004 National Institute of Standards and TechnologyDepartment of Commerce
  9. A METHOD TO PREDICT SEPARATION DELAY ON AIRFOILS DUE TO VORTEX GENERATORS

    Amount: $70,000.00

    N/A

    SBIR Phase I 1996 National Aeronautics and Space Administration
  10. Multidisciplinary Design Opimization (MDO)

    Amount: $548,902.00

    A Cartesian, multigrid, Euler solver is investigated for development as a module suitable for the multidisciplinary design optimization (MDO) environment. The ultimate objective is not to improve the ...

    SBIR Phase II 1996 Air ForceDepartment of DefenseDepartment of Defense

Agency Micro-sites

US Flag An Official Website of the United States Government